Labgenomics Co Rule of 40
The Rule of 40 of Labgenomics Co (084650.KQ) as of Oct 27, 2026 is -5.39 %. In the previous year, Rule of 40 was -60.28 % — a change of -91.06% (higher).
Get this data via API
Financial Data API
Rule of 40
-5.39 %
YoY
-91.06%
Last updated:
Rule of 40 of Labgenomics Co is 2024 -5.39 % . Rule of 40 of Labgenomics Co was 2023 -60.28 % . It decreases by -91.06% higher compared to the previous year.
The Labgenomics Co Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2017
-8.73 KRW
Jan 1, 2018
-0.70 KRW
Jan 1, 2019
22.81 KRW
Jan 1, 2020
304.72 KRW
Jan 1, 2021
121.05 KRW
Jan 1, 2022
17.26 KRW
Jan 1, 2023
-60.28 KRW
Jan 1, 2024
-5.39 KRW
| YEAR | Rule of 40 | YoY |
|---|---|---|
| -5.39 % | -91.06% | |
| -60.28 % | -449.33% | |
| 17.26 % | -85.74% | |
| 121.05 % | -60.28% | |
| 304.72 % | +1,236.14% | |
| 22.81 % | -3,377.57% | |
| -0.70 % | -92.03% | |
| -8.73 % | -548.24% | |
| 1.95 % | -67.82% | |
| 6.05 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Labgenomics Co Stock analysis
What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio.
The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care.
LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Labgenomics Co stock
Rule of 40 of Labgenomics Co is -5.39 % in 2024.
On Eulerpool you can find the complete historical development of Rule of 40 Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Labgenomics Co
All Key Metrics — Labgenomics Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth